Comparison of CEAC, BEAM, and IEAC Conditioning Regimens Followed by Autologous Stem Cell Transplantation in Peripheral T Cell Lymphoma Patients

Scientists retrospectively compared the outcomes of 52 PTCL patients treated with lomustine, etoposide, cytarabine, and cyclophosphamide (CEAC), carmustine, etoposide, cytarabine and melphalan (BEAM) and idarubicin, etoposide, cytarabine and cyclophosphamide (IEAC) regimens followed by autologous stem cell transplantation at their center between 2012 and 2021.